aTyr Pharma announced that it has commenced an underwritten public offering of shares of its common stock. aTyr intends to use the net proceeds from the offering primarily for general corporate purposes, including the ongoing development of efzofitimod and the expansion of its clinical development program to include a planned Phase 2 study of efzofitimod in patients with systemic sclerosis-associated interstitial lung disease, in 2023, based on recent clearance of an Investigational New Drug application by the FDA, and for working capital. RBC Capital Markets is acting as sole book-running manager for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LIFE:
- aTyr Pharma Announces Commencement of Public Offering of Common Stock
- aTyr Pharma announces achievement of milestone by partner Kyorin Pharmaceutical
- aTyr Pharma to present new data on mechanism of action of efzofitimod
- aTyr: EPO okays use of efzofitimod with pirfenidone patent for lung inflammation
- aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
